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Abstract 
Background: Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is an X‑linked genetic disorder that results in 
impaired enzyme activity. Although G6PD deficiency is globally distributed it is more prevalent in malaria‑endemic 
countries. Several mutations have been identified in the G6PD gene, which alter enzyme activity. The G6PD genotype 
predominantly found in sub‑Saharan Africa is the G6PDB (G6PD376A) with (G6PD376G) and G6PDA‑ (G6PD376G/202A, 
G6PD376G/542T, G6PD376G/680T and G6PD376G/968C) occurring at lower frequencies.
Aim: The aim of this study was to identify the prevalence of G6PD deficiency and asymptomatic Plasmodium falcipa-
rum carriage in children living in southern Ghana and determine whether G6PD deficiency influences asymptomatic 
carriage of P. falciparum parasites.
Methods: Blood samples were obtained once a month from 170 healthy Ghanaian school children aged between 5 
and 12 years from Basic schools in two communities Obom and Abura with similar rainfall patterns and malaria peak 
seasons. G6PD enzyme activity was assessed using the qualitative G6PD RDT kit (AccessBIO). G6PD genotyping and 
asymptomatic parasite carriage was determined by PCR followed by restriction fragment length polymorphism (RFLP) 
of DNA extracted from dried blood spots.
Results: The only sub‑Saharan G6PD A‑ allele detected was the A376G/G202A found in 12.4 % (21/170), of the 
children and distributed as 4.1 % (7/170) A‑, 1.8 % (3/170) A‑/A‑ homozygous deficient males and females and 6.5 % 
(11/170) A/A‑ and B/A‑ heterozygous deficient females. Phenotypically, 10.6 % (15/142) of the children were G6PD 
deficient. The asymptomatic carriage of P. falciparum by PCR was 50, 29.4, 38.2 and 38.8 % over the months of Febru‑
ary through May 2015, respectively, and 28.8, 22.4, 25.9 and 5.9 % by microscopy during the same periods.
Conclusions: G6PD deficiency was significantly associated with a lowered risk of PCR‑estimated asymptomatic  
P. falciparum carriage in children during the off peak malaria season in Southern Ghana.
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Background
Malaria is a deadly disease caused by five Plasmodium 
species with Plasmodium falciparum being the most 
lethal. Plasmodium falciparum caused an estimated 
438,000 deaths globally in 2015 [1]. The heaviest burden 
of malaria, according to the World Health Organization 
(WHO), is in Africa where an estimated 395,000 malaria 
deaths was recorded in 2015 [1].
G6PD deficiency (G6PDd) is one of the most com-
mon human genetic enzyme defects [2], affecting over 
400 million people. Although this enzymopathy is glob-
ally distributed, it is more prevalent in the tropics and 
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sub-tropics, especially in malaria-prone countries [3]. This 
X-linked genetic condition is characterized by reduced 
G6PD enzyme activity, which can remain asymptomatic. 
Red blood cells obtain reduced glutathione (GSH) solely 
from the G6PD/reduced nicotinamide adenine dinucleo-
tide phosphate (NADH) pathway. The deficiency makes 
red cells more susceptible to oxidative haemolysis that can 
be triggered by certain drugs, such as primaquine (PQ) 
and other 8-amino quinolone drugs [4]. Glucose-6-phos-
phate dehydrogenase (G6PD) and a number of other 
human genetic traits including sickle cell anaemia and 
related haemoglobinopathies are predominantly found in 
populations living in malaria endemic countries and have 
been suggested to provide the host protection from severe 
forms of malaria [5–8] and asymptomatic malaria [9]. 
A number of genetic traits that protect the host against 
severe forms of malaria have recently been found to pro-
mote the development of the sexual transmissible stages 
of the parasite, and individuals with these traits serve as 
reservoirs for malaria transmission [10] or alter the acqui-
sition of anti-parasite antibodies [11].
G6PD deficiency can be determined using a number of 
approaches, including, quantitative tests, which measure 
precise enzyme activity, qualitative tests which classify 
enzyme activity as normal or deficient and genetic tests, 
which identify gene mutations [12–19].
Over 400 G6PD variants have been identified [4] and 
the polymorphisms are predominantly defined to specific 
geographic locations [20]. In sub-Saharan Africa, the pre-
dominant G6PD variants are B, A and A-, with frequen-
cies greater than 1 %. The G6PD B variant has the 376A 
cDNA sequence and is classified as possessing normal 
enzyme activity. The non-deficient G6PD A variant has 
been shown to possess about 85 % of the activity of the 
normal enzyme and is classified as possessing normal 
activity carries a cDNA mutation A376G, which trans-
lates into amino acid N126D. The sub-Saharan G6PD 
A- variants carry the G6PD A backbone with an addi-
tional single mutation, the most common A- variant has 
the A376G/G202A cDNA mutation. G6PD A- been sug-
gested to possess 10 % of normal enzyme activity in their 
red blood cells though their white blood cells maintain 
100  % normal enzyme activity [21] Additional A- vari-
ants peculiar to sub-Saharan Africa include the A376G/
A543T, A376G/G680T and A376G/T968C [19].
Global efforts to achieve malaria elimination have lead 
the WHO to recommend PQ, the only WHO certified 
anti-gametocyte drug, to be incorporated into malaria 
treatment regimens in selected countries to reduce 
malaria transmission [22]. Although low-dose PQ has 
been found to be safe for use in G6PDd individuals [23, 
24], a number of other reports have found PQ to cause 
dangerous side effects in G6PDd individuals [25, 26] 
making it necessary to monitor the prevalence of G6PD 




Abura Dunkwa, also known as Abura, is the district capi-
tal for Abura-Asebu-Kwamankese district of the Central 
Region with a rural population of 31,768 for children 
under 14  years of age [27]. Obom is in the Ga south 
municipality of the Greater Accra Region with a rural 
population of 22,368 for children under 14  years of age 
[28]. Abura (Cape Coast) is an area of seasonal malaria 
transmission and Obom (Accra) is an area of peren-
nial malaria transmission, both of which have the peak 
malaria season between June to August. Inhabitants of 
these regions have different ethnicities. Although a total 
of 200 school children aged from six through 12  years 
were recruited for this study, 30 missed at least one 
of the four sampling days. Out of the 170 children, 150 
were randomly selected for phenotypic analysis of G6PD 
enzyme activity.
Microscopic estimation of malaria parasite
Thick and thin blood smears as well as dried filter paper 
blood spots (DBS) were each made from a drop (~50 μl) 
of finger-prick blood. The slides were air-dried, the thin 
smear fixed in methanol and both smears stained with 
10 % Giemsa for 15 min. The stained slides were subse-
quently air-dried and viewed under 100X oil immersion 
microscope. Two independent microscopists read the 
slides. Parasitaemia was determined as the % of malaria 
parasites observed per 200 white blood cells (WBCs).
DNA extraction from dried blood spots
DNA and antibodies were extracted from the DBS [29]. 
Briefly, two 3  mm disks were punched from the fil-
ter paper blood blots into a 2  ml microcentrifuge tube. 
The tube was then filled with 1120  μl of 0.5  % saponin 
and left to shake overnight at room temperature. The 
saponin supernatant containing the eluted antibodies 
was decanted and saved for the ELISAs. The disks were 
washed for 30 min in ice cold PBS at 4 °C. The wash solu-
tion was decanted and the tubes filled with 150 μl of 6 % 
chelex in PBS. The tubes were then heated at ~99 °C for 
30 min with a quick vortex and centrifuge every 10 min. 
The heat extracted DNA was aliquoted into a new tube 
and either used immediately or stored at 4  °C for use 
within 2 weeks.
Plasmodium falciparum genotyping
MSP2 and/or GLURP genotyping was performed on the 
extracted gDNA to simultaneously determine parasite 
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prevalence and diversity. The WHO malaria parasite gen-
otyping protocol (23) was followed with slight modifica-
tions. PCR reactions were carried out in 15  μl volumes 
for both the primary and nested reactions. Briefly the 
200 nM M2-0F and M2-0R primers were used to amplify 
4 μl of extracted DNA using One Taq polymerase (NEB). 
The nested reaction was carried out using 1 μl of the pri-
mary PCR product with 200 nM each of the combination 
of S1Fw/N5rev for the 3D7 type alleles or S1Fw/M5rev 
for the FC27 type alleles. For GLURP, the G-F3 and G-F4 
primer pair was used for the outer PCR reaction and the 
G-NF and G-F4 primer pair used for the nested inner 
reaction. All the PCR fragments and the digested prod-
ucts were viewed under UV after resolving on a 2 % aga-
rose gel containing 0.5 µg/ml ethidium bromide.
G6PD enzyme activity
Rapid detection of enzyme activity was determined using 
the G6PD rapid diagnostic test kits (Access BIO, USA) 
according to manufacturer’s instructions. Briefly, the 
finger was pricked with a lancet provided in the kit and 
the blood spotted on to the sample pad of the test cas-
sette. Two drops of buffer was applied to the sample pad 
and after 15 min the colour of the sample pad was noted. 
A purple membrane indicated normal enzyme activity 
whilst a white membrane indicated enzyme deficiency.
G6PD genotyping
PCR was performed on DNA extracted from the DBS as 
previously reported [30]. The A376G polymorphism was 
analysed in each DNA sample using PCR followed by 
digestion with 1 unit of FOKI restriction enzyme under 
manufacturer-recommended conditions in a thermal 
cycler. Only those samples that were 376G and thus pro-
duced a digested product were further analysed for three 
other sub-Saharan African cDNA mutations, G202A, 
G680T and T968C by similar restriction fragment length 
polymorphism. The G202A PCR amplicon was digested 
with NlaIII restriction enzyme, the G680T amplicon was 
digested with BstNI restriction enzyme and the T968C 
amplicon digested with NciI restriction enzyme for 1 h at 
37 °C. All the PCR fragments and the digested products 
were viewed under UV after resolving on a 2 % agarose 
gel containing 0.5 µg/ml ethidium bromide.
Statistical analysis
Microsoft excel and SPSS 22.0 (IBM Corp) were used for 
all data analysis and to generate the frequency and cross 
tabulation tables. Frequency of parasite carriage was cal-
culated as the (Additional file  1) sum of the number of 
times a child was observed to be parasite positive over 
the four time points. SPSS linear regression was used 
with model fit analysis to identify significant correlations 
between frequency of parasite carriage estimated by 
microscopy and PCR (dependent variables) and G6PD 
genotype and phenotype (independent variables). The 
relationship between G6PD genotype and phenotype was 
obtained using crosstabs descriptive statistics. Statistical 
significance was defined as p value  ≤0.05.
Results
Study site
The study utilized blood samples collected from a lon-
gitudinal survey of children living in southern Ghana 
(Fig. 1) from February through May 2015. Two hundred 
study participants were recruited but the data presented 
analysed samples from 170 children who were avail-
able for all four blood collection visits. The mean age of 
the children was 9.12 ±  0.13 however 45  % of the chil-
dren were either nine or 10 years old. Fifty-four percent 
(92/170) of the children were female (Table 1), however 
the ratio was slightly increased to 56  % (80/142) in the 
subset used for the G6PD phenotype analysis. None of 
the children were symptomatic for malaria during any of 
the sampling visits.
G6PD phenotype
Out of the 150 children sampled with the G6PD RDT, 
8 gave invalid results. From the 142 valid test results, 
10.6 % (15/142) were branded G6PD deficient, with boys 
representing 47 % (7/15) of the total G6PDd population 
(Table 1). Ninety-one percent and 85 % of boys and girls 
respectively carried normal G6PD genotypes while 89 
and 90 % of boys and girls were characterized as possess-
ing normal G6PD enzyme activity (Table 1).
G6PD genotype
The only G6PD A- genotype identified was A376G/
G202A, which was identified in seven hemizygous 
G6PDd (A-) males, 11 heterozygous G6PDd females 
(B/A-, A/A) and three homozygous G6PDd (A-/A-) 
females, representing 4.1, 6.5 and 1.8 % of the 170 school 
children respectively (Table 1).
Microscopic and PCR estimation of parasite carriage
The monthly P. falciparum prevalence estimated by PCR 
for February through May 2015 was 50 % (85/170), 29.4 % 
(50/170), 38.2  % (65/170) and 38.8  % (66/170) (Fig.  2a). 
PCR parasite genotyping identified 20 % (34/170) of the 
children to have remained parasite free during all the 
four visits, 29.4  % (50/170) to have been parasite posi-
tive at least once during the four visits, 30.6 % (52/170) 
to have had parasites on two visits, 14.7 % (25/170) to be 
parasite positive on three visits and 5.3 % (9/170) to have 
persistently carried parasites during each monthly visit 
(Fig. 1b).
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Microscopy estimated P. falciparum prevalence for 
February through May 2015 as 28.8  % (49/170), 22.4  % 
(38/170), 25.9  % (44/170) and 5.9  % (10/170) (Fig.  2a). 
The proportion of children who remained parasite free by 
microscopy during all the four visits was 50.6 % (86/170), 
those that were positive at least once during the four vis-
its was 26.5 % (45/170). The proportion of children who 
were parasite positive at two and three visits was 12.9 % 
(22/170) and 10  % (17/170) respectively. No child was 
identified as harbouring microscopic parasites at each of 
the four visits (Fig. 2b).
PCR detected a much higher prevalence of parasites 
than microscopy during each of the four survey points. 
Sub-microscopic P. falciparum carriage was estimated 
as the number of children with PCR detectable parasites 
who were classified as parasite negative by microscopy. 
Due to the much higher prevalence of parasites detected 
by PCR, sub-microscopic parasite carriage by the chil-
dren during the survey period was generally high, espe-
cially in May when microscopic parasite carriage was the 
lowest.
G6PD status and asymptomatic Plasmodium falciparum 
carriage
Neither sub-microscopic parasite carriage nor micro-
scopic parasite carriage over the 4  months was signifi-
cantly associated with G6PD genotype and phenotype 
when tested with the model fit linear regression model 
(p > 0.05). However, parasite carriage estimated by PCR 
was significantly associated G6PD genotype but not 
Fig. 1 Map showing the location of study sites. Children were selected from four schools, two each in Obom in the Ga South municipality of the 
Greater Accra Region and Abura, in the Cape Coast municipality of the Central Region. Both sites lie on the southern coast of Ghana
Table 1 Distribution of  G6PD genotype and  phenotype 
by sex
Deficient (P), deficient G6PD enzyme activity; Normal (P), normal G6PD enzyme 
activity; Deficient (G), deficient genotype (A- and A-/A-); Heterozygous deficient 
(G), female heterozygous deficient (A/A- and B/A-); Normal (G), normal genotype 
(A, B, A/A, A/B and B/B)
Deficient (P) Deficient (G) Heterozygous 
deficient (G)
Female 5.6 % (8/142) 1.8 % (3/170) 6.5 % (11/170)
Male 4.9 % (7/142) 4.1 % (7/170) 0 % (0/170)
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G6PD phenotype (p < 0.05) (Table 3). There was a trend 
of a child having a lower tendency to carry malaria para-
sites at all four sampling times with both the G6PDd and 
the G6PDn children (Fig. 3a–d).
Comparison of G6PDd prevalence by phenotypic RDT 
and PCR genotyping
Less than 5 % of children with normal G6PD genotypes 
were found to possess normal enzyme activity, however 
almost 50  % (44–56  %) of the hemi and homozygous 
deficient as well as the heterozygous deficient G6PD 
genotypes were found to possess normal enzyme activity 
using the qualitative G6PD RDT kits (Table 2).
Discussion
In order to identify any possible influence of G6PD defi-
ciency on asymptomatic malaria carriage, this study 
was conducted over the off peak malaria season, from 
February through to May 2015, when symptomatic P. 
falciparum carriage is low. Some previous studies have 
identified relationships between G6PD deficiency and 
protection from severe malaria [2, 31] as well as asymp-
tomatic status [9]. In Ghana, however, most studies have 
concentrating on pregnant women due to the national 
sulfadoxine-pyrimethamine intermittent preventative 
treatment in pregnant women (SP-IPTp) policy [32–35]. 
Very few studies have focused on asymptomatic malaria 
patients or simultaneously carried out genotypic and 
phenotypic analysis of G6PD on the same individual [30, 
36] as such, this study set out to find a possible correla-
tion of G6PD with asymptomatic malaria in Ghana.
Asymptomatic parasite carriage estimated by PCR was 
very high, averaging about 40 % over the 4 months of the 
study (Fig.  2a). An average of 26  % of the children were 
identified as asymptomatic for malaria by microscopy for 
the first 2 months (February to April). The asymptomatic 
status of the children who tested positive for P. falciparum 
was confirmed by the fact that none of the children had a 
fever of 37.5 °C and above or any other physical symptoms 
of malaria during any of the four blood draws. Such high 
levels of asymptomatic P. falciparum carriage suggests 
that the children have developed immunity to malaria and 
serve as reservoirs for the parasite, which is likely to be a 
channel for intense malaria transmission when the mos-
quitoes start breeding during the rainy season.
The high prevalence (23 %) of samples, of children who 
were found to be parasite positive by microscopy more 
than once during the 4  monthly visits (Fig.  2b) could 
explain the sustained transmission of malaria imme-
diately after the rainy season begins as there is a possi-
ble continuous production of gametocytes from these 
asexual parasites. The superiority of PCR over micros-
copy, the gold standard for the detection and diagnosis 
of malaria was confirmed in this study as the number of 
children found to be P. falciparum parasite free over the 
entire study period reduced from 50.6 % as observed by 
microscopy to 20 % after PCR analysis (Fig. 2b).
This study identified only the 376G/202A G6PDA- var-
iant, which has so far been the only G6PD variant identi-
fied in Ghana [9, 30, 36]. The prevalence of G6PDd, of % 
(7/170) A- males and 1.8 % (3/170) A-/A- females identi-
fied in the study population (Table 1) is lower than pre-
viously published for Ghana [30]. The difference could 
be due to the use of a study population inhabiting the 
southern coast of Ghana as a previous report has shown 
that the prevalence of G6PDd in both males and females 
is higher in Kintampo, which is to the north of Kumasi 
than in Kumasi, which is in the middle belt of Ghana 
Fig. 2 a P. falciparum parasite prevalence estimated by microscopy and PCR. Giemsa stained thick blood smears from samples collected monthly 
from a set of children were read and used to estimate parasite prevalence. PCR analysis of gDNA extracted from these same samples was also used 
to estimate parasite prevalence. b The number of times any particular child was classified as P. falciparum positive by either microscopy or PCR over 
the 4 month period was documented
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[30]. Forty four percent of G6PD A- and A-/A- children 
possed normal enzyme activity (Table 2) which is higher 
than that perviously reported in a study conducted in six 
African countrie including Ghana, where 10 % of G6PD 
A- males and 24 % G6PD A-/A- females possessed nor-
mal enzyme activity [30].
A previous study conducted in Ghana found G6PDd 
children to be about 1.5 times more likely to be parasi-
taemic based on microscopic evaluation of thin and thick 
blood films than non-deficient children [37], suggesting 
that the G6PD deficiency was associated with marginal 
susceptibility to clinical malaria in a child under 5 years 
of age. This study involved slightly older children who did 
not display such an association of G6PDd and malaria. 
PCR detectable parasite carriage but not parasite carriage 
by microscopy was significantly (p  =  0.038) associated 
with the G6PD normal genotype (Table  3, Additional 
file 1), which slightly supports previous reports that sug-
gests the G6PD trait offers some protection from malaria 
[38, 39]. G6PD deficient children also had a lower ten-
dency to carry sub-microscopic P. falciparum parasites 
more than once during the 4  month period (Fig.  3a) 
although some G6PDd deficient children carried micro-
scopically detectable parasites three out of the four sam-
ple visits (Fig. 3b).
Genotyping G6PD by RFLP analysis identifies only the 
known G6PD genotypes, leaving the possibility of iden-
tifying novel mutations, which could possibly impact 
enzyme activity (28). A sample can be misclassified 
as normal due to the absence of particular mutations 
Fig. 3 Frequency of P. falciparum carriage in G6PD normal and deficient children. Cumulative incidence of observed parasite carriage (microscopic 
and sub microscopic) in children classified as either G6PD normal or deficient by genotyping or RDT kit phenotypng over the 4 monthly visits. 
Frequency of microscopic (a) and sub microscopic parasite (b) parasite carriage within the three G6PD genotype groups, deficient (A‑ and A‑/A‑); 
Heterozygous deficient (A/A‑ or B/A‑) and Normal (A, B, A/A, A/B, B/B)
Table 2 Analysis of G6PD genotype and phenotype
Deficient (P), deficient RDT read out; Normal (P), normal RDT read out; Deficient 
(G), deficient gene variant (A- and A-/A-); Heterozygous deficient (G), female with 
a heterozygous genotype (A/A- or B/A-); Normal (G), gene variants known to 
posses normal g6pd enzyme activity (A, B, A/A, A/B, B/B). All the samples were 
analysed for G6PD enzyme activity using the qualitative CareStart™ G6PD RDT 
kits as well as the presence of the sub Saharan African G6PD gene variants
Deficient (P) Normal (P)
Deficient (G) 55.6 % (5/9) 44.4 % (4/9)
Heterozygous deficient (G) 44.4 % (4/9) 55.6 % (5/9)
Normal (G) 4.8 % (6/124) 95.2 % (118/124)
Table 3 Summary of linear regression analysis
G6PD (P), G6PD phenotype; G6PD (G), G6PD genotype
a Dependent variable: frequency of PCR detectable parasite carriage
b Dependent variable: frequency of Microscopic parasite carriage
c Dependent variable: frequency of sub microscopic parasite carriage
Model fit Standardized coefficientsa Siga. (PCR) Standardized coefficientsb Sigb. (Micro) Standardized coefficientsc Sigc. (SM)
Beta (PCR) Beta (Micro) Beta (SM)
(Constant) 0.032 0.009 0.103
G6PD (P) −0.03 0.707 −0.011 0.89 0.126 0.112
G6PD (G) 0.166 0.038 0.02 0.8 0.133 0.093
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characterized despite carrying mutations that were not 
analysed. The six children who did not carry an A- allele 
but were identified as having reduced G6PD enzyme 
activity (Table  2) could have possessed other deficiency 
causing mutations that were not characterized pos-
sibly because they have not been assigned a genotype 
[40]. A study conducted in the Gambia on 1437 children 
between 5 and 14 years found half (50 %) the study popu-
lation to carry the G6PD A376G (B) variant and 39 % to 
carry mutations that have not been assigned a genotype 
[41]. Heterozygous G6PD deficient females are able to 
randomly inactivate one of their two X-chromosomes 
and as such exhibit either normal or deficient G6PD 
enzyme activity [42, 43]. As such a little over half (5/9) 
of the heterozygous deficient children exhibited normal 
G6PD enzyme activity.
The CareStart™ G6PD RDT classified 44.4  % (4/9) of 
A- and A-/A- deficient children as normal (to possess 
normal G6PD enzyme activity). This could be due to 
inaccuracies and the level of subjectivity of the RDT kit 
readout [13, 14, 16, 44]. Some studies have found people 
with the same G6PD cDNA mutation to exhibit different 
enzyme activities due to possible differences in the G6PD 
acetylator in the deficient persons [45] as well as the pos-
sible contribution of a number of superimposed genetic 
deficiencies [46] and blood sugar levels [47].
Limitations
Genetic analysis of G6PD deficiency was carried out 
using RFLP and specifically determined common sub-
Saharan African G6PD genotypes. As such other defi-
ciency causing mutations which were not analysed could 
have been present in the study population. Additional 
characterization of red blood cells were not performed 
although certain red blood cell conditions such as anae-
mia, which causes a reduction in the volume of older 
G6PDd RBC’s and an increase in reticulocytes, could 
result in anaemic G6PDd child exhibiting near normal 
G6PD enzyme activity [48]. A disadvantage to the rapid 
qualitative CareStart™ G6PD RDT kit used for G6PD 
phenotypic analysis is that read out can be subjective and 
a few sample results could have been misinterpreted.
Conclusions
Asymptomatic P. falciparum carriage over the off peak 
malaria season of 30 to 50  % could likely be a driv-
ing force to sustained malaria transmission over the off 
peak season. Twelve percent of the school children car-
ried genetically deficient G6PD genes and 11  % were 
identified as having deficient G6PD enzyme activity. The 
frequency of parasite carriage estimated by PCR was sig-
nificantly associated with G6PD phenotype. A similar 
study should be conducted in the peak malaria season to 
determine the consequences asymptomatic P. falciparum 
carriage has on malaria transmission as well as identify 
association between G6PD and malaria in these same 
children during the peak season.
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